Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Calyxt, Inc. (Nasdaq: CLXT) has successfully completed a 1-for-10 reverse stock split of its common stock, effective April 24, 2023. This decision was approved by shareholders on June 1, 2022, and aims to enhance the company's stock price and maintain compliance with Nasdaq listing standards. Post-split, the number of outstanding shares has decreased from approximately 49.7 million to about 5 million, but the total authorized shares remain unchanged. The stock will resume trading on an adjusted basis on April 25, 2023, under the symbol CLXT and a new CUSIP number. The company’s equity-based awards will be adjusted proportionately. No action is required from registered stockholders as their holdings will be automatically updated.
Cellectis has announced the implementation of alemtuzumab as an Investigational Medicinal Product (IMP), coded CLLS52, in its clinical trials for UCART22, UCART123, and UCART20x22. This addition to the lymphodepletion regimen has shown prolonged lymphodepletion and increased cell expansion leading to greater clinical activity. The trials focus on patients with relapsed/refractory B-cell ALL, AML, and NHL. This collaboration with Sanofi, which began in May 2021, involves the supply of alemtuzumab for these studies. The findings from the BALLI-01 and AMELI-01 studies are promising, indicating a significant step forward for Cellectis' allogeneic CAR T-cell therapies, enhancing their therapeutic potential against various cancers.
